Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection

被引：65

作者：

Barbaro, G ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Med Pathophysiol, Rome, Italy

来源：

CURRENT HIV RESEARCH | 2006年 / 4卷 / 01期

关键词：

human immunodeficiency virus; highly active antiretroviral therapy; nucleoside reverse transcriptase inhibitors; protease inhibitors; metabolic syndome; cardiovascular disease;

D O I：

10.2174/157016206775197664

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Highly active antiretroviral therapy (HAART) regimens, especially those including protease inhibitors have been shown to cause, in a high proportion of HIV-infected patients, a metabolic syndrome (lipodystrophy/lipoatrophy, dyslipidemia, type 2 diabetes mellitus, insulin resistance) that may be associated with an increased risk of cardiovascular disease. A careful stratification of the cardiovascular risk of HIV-infected patients under HAART is needed according to the most recent clinical guidelines.

引用

页码：79 / 85

页数：7

共 56 条

[1] Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy [J].

Addy, CL ;

Gavrila, A ;

Tsiodras, S ;

Brodovicz, K ;

Karchmer, AW ;

Mantzoros, CS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (02) :627-636

[2]

Alonso-Villaverde C, 2005, AIDS, V19, P341

[3] Hypertension in the HIV-infected patient [J].

Aoun S. ;

Ramos E. .

Current Hypertension Reports, 2000, 2 (5) :478-481

[4] An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy [J].

Barbaro, G ;

Di Lorenzo, G ;

Cirelli, A ;

Grisorio, B ;

Lucchini, A ;

Hazra, C ;

Barbarini, G .

CLINICAL THERAPEUTICS, 2003, 25 (09) :2405-2418

[5] Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors:: Association with the development of lipodystrophy [J].

Bonnet, E ;

Ruidavets, JB ;

Tuech, J ;

Ferrières, J ;

Collet, X ;

Fauvel, J ;

Massip, P ;

Perret, B .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01) :296-302

[6] Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection [J].

Bozzette, SA ;

Ake, CF ;

Tam, HK ;

Chang, SW ;

Louis, TA .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) :702-710

[7] Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the multicenter AIDS cohort study [J].

Brown, TT ;

Li, XH ;

Cole, SR ;

Kingsley, LA ;

Palella, FJ ;

Riddler, SA ;

Chmiel, JS ;

Visscher, BR ;

Margolick, JB ;

Dobs, AS .

AIDS, 2005, 19 (13) :1375-1383

[8] The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro [J].

Caron, M ;

Auclair, M ;

Lagathu, C ;

Lombès, A ;

Walker, UA ;

Kornprobst, M ;

Capeau, J .

AIDS, 2004, 18 (16) :2127-2136

[9] Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation [J].

Caron, M ;

Auclair, M ;

Sterlingot, H ;

Kornprobst, M ;

Capeau, J .

AIDS, 2003, 17 (17) :2437-2444

[10] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].

Carr, A ;

Samaras, K ;

Burton, S ;

Law, M ;

Freund, J ;

Chisholm, DJ ;

Cooper, DA .

AIDS, 1998, 12 (07) :F51-F58

← 1 2 3 4 5 6 →